Influence of the ABCB1-rs1045642 gene polymorphism on blood drug concentration in voriconazole-treated patients with a severe invasive fungal infection

Qian Zhang Xing Gao Dongmei Lv ^*

• Xuzhou Medical University, Xuzhou, China

This study aimed to investigate the impact of the ABCB1-rs1045642 gene polymorphism on the blood drug concentration of voriconazole in patients with severe invasive fungal infections. A total of 101 patients treated with voriconazole were enrolled. Polymerase Chain Reaction and Sanger sequencing were used to detect the genotype of ABCB1-rs1045642, and enzyme amplified immunoassay was used to detect voriconazole plasma trough concentration. To analyze the impact of patient genotype and the minimum concentration of voriconazole, and investigate the treatment efficacy and the rate of adverse reactions in patients with different genotypes. 101 subjects received standard-dose voriconazole treatment for 1 week, the mean plasma concentration was 4.5 (3.10, 6.90) mg/L. ABCB1-rs1045642 had three genotypes in 101 patients: the wild type (CC type), the heterozygous mutant type (CT type), and the homozygous mutant type (TT type). There were 18 TT type cases, 48 CT type cases, and 35 CC type cases. Patients with different genotype groups and varying plasma trough concentrations did not differ statistically significantly in terms of treatment efficacy or incidence of adverse events. Voriconazole plasma concentrations differ significantly among patients with different genders and ABCB1-rs1045642 genotypes. Incorporating gender into the multiple regression model. The regression equation C1=6.09-1.33×Gender (male=0, female=1)-0.47× X1 (X1: T/T=1, non-T/T=0); C2=6.09-1.33×Gender (male=0, female=1)-0.94×X1 (X1: T/T=1, non-T/ T =0). The ABCB1-rs1045642 genotype was not found to affect voriconazole plasma trough concentration in intensive care unit patients with invasive fungal infections.